lobbying_activities: 1588066

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1588066	90aba804-470a-4c3e-96a3-54136069acd5	Q3	APOTEX CORP.	310973	APOTEX CORP.	2014	third_quarter	PHA	FDA proposed rule,Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; HR 5657, the Fair Acess for Safe and Timely Generics Act of 2014, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; Federal policy relating to issues affecting the generic drug industry within the House Energy and Commerce Committee's 21st Century Cures initiative; Federal policy relating to International Nonroprietary Names for Biosimilars; and, Implementation of Public Law 112-144 - The Food and Drug Administration Safety and Innovation Act, federal policy relating to provisions in Title 3 regarding generic drug user fees.	HOUSE OF REPRESENTATIVES,SENATE		130000	0	0	2014-10-16T09:31:46.353000-04:00